Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Solvonis Therapeutics ( (GB:SVNS) ) is now available.
Solvonis Therapeutics plc has successfully raised £1.25 million through a direct subscription with institutional and strategic investors to accelerate its programs in high-burden CNS disorders. This funding will support the company’s expanded three-pillar strategy focusing on addiction, psychiatry, and neurology, enabling Solvonis to advance its clinical and pre-clinical programs, expand its CNS drug-discovery efforts, and strengthen its R&D capabilities. The investment marks a significant step in Solvonis’ growth as it aims to deliver innovative therapies for CNS disorders, enhancing its industry positioning and providing a foundation for continued scientific and clinical progress.
More about Solvonis Therapeutics
Solvonis Therapeutics plc is an emerging biopharmaceutical company focused on developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, the company is advancing a differentiated pipeline across addiction, psychiatry, and neurology, with lead programs addressing Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
Average Trading Volume: 72,766,787
Technical Sentiment Signal: Buy
Current Market Cap: £22.73M
For an in-depth examination of SVNS stock, go to TipRanks’ Overview page.